BioSpace News Archive

CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, issues a stockholder letter from Chief Executive Officer, Dr. Phillip Chan.

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that it will be participating in the following upcoming investor conferences

Generation Bio Co., an innovative genetic medicines company creating a new class of gene therapy, announced that Ron Cooper has been appointed to its Board of Directors.

Nephros, Inc., a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, announced the appointment of Wes Lobo as Chief Marketing Officer, reporting directly to Nephros Chief Executive Officer, Andy Astor.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive officer is scheduled to participate in four upcoming virtual investor conferences:

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021.

Intellia Therapeutics, Inc., a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its fourth quarter and full-year 2020 financial results and operational highlights in a conference call on February 25, 2021 at 8 a.m. ET.

Cytokinetics, Incorporated announced that Muna Bhanji has been appointed to the company’s Board of Directors.

Translate Bio announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the SVB Leerink Virtual 10th Annual Global Healthcare Conference on Friday, February 26, 2021 at 9:20 a.m. EST.

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced plans to advance FX201 into the high dose cohort of the Phase 1 dose-escalation trial.